Moderna (NASDAQ:MRNA) and Merck (NYSE:MRK) announced Tuesday that their individualized neoantigen therapy continues to show dramatic long-term benefits, providing the strongest evidence to date that mRNA technology can be harnessed to treat established cancer.
Rockwell Medical (NASDAQ:RMTI) announced preliminary unaudited financial results for the fourth quarter and full-year 2025, signaling a successful operational turnaround following a year of heavy customer transition.
ImmunityBio (NASDAQ:IBRX) is moving toward a significant label expansion for its first-in-class immunotherapy, ANKTIVA® (nogapendekin alfa inbakicept), following a pivotal Type B meeting with the U.S. Food and Drug Administration (FDA).
Guardant Health (NASDAQ:GH) has secured an expansive multi-year collaboration with Merck (NYSE:MRK) to integrate its high-sensitivity liquid biopsy technology into Merck’s global oncology development program.
Immuron (NASDAQ:IMRN) achieved record first-half sales for its lead commercial product, Travelan®, reporting a 5% year-over-year increase in global revenue to AUD$4.2 million.
Mesoblast shares were in focus Monday after the company announced positive formal feedback from the U.S. Food and Drug Administration (FDA) regarding its allogeneic cell therapy, rexlemestrocel-L.
The European Medicines Agency (EMA) has officially commenced its review of ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab, a move that could soon establish the antibody-drug conjugate (ADC) as a primary treatment for HER2-positive metastatic breast cancer in the European Union.
Harbour BioMed has transitioned from a traditional licensor to a significant shareholder in Spruce Biosciences, exercising warrants to acquire a nearly 4% stake in the California-based rare disease specialist.
Sila Realty Trust (NYSE:SILA) completed the $43.1 million acquisition of the Nobis OKC Facility on Friday, a move that underscores the REIT’s strategy of targeting market-dominant healthcare assets with high occupancy and limited competition.
ImmunityBio (NASDAQ:IBRX) announced on Friday that its mission to redefine the first-line treatment for bladder cancer is moving faster than anticipated, putting a critical regulatory filing within reach for late 2026.
Axsome Therapeutics (NASDAQ:AXSM) announced on Thursday that it has dosed the first patient in its FORWARD Phase 3 clinical trial, a pivotal step in the development of AXS-14 (esreboxetine) for the management of fibromyalgia.
Neurocrine Biosciences (NASDAQ:NBIX) presented the first head-to-head imaging data on Thursday comparing the brain-binding potency of the two leading treatments for involuntary movement disorders.
